Evaluation of effervescent floating matrix tablet formulations of salbutamol sulfate using full factorial design

Asian Journal of Pharmaceutics

Volumn 3, Issue 1, 2009, Pages 43-49

  Rao, Monica R P ^a,b   Sonar, Girish S ^a   Mandsaurwale, Rachana R ^a   Vanshiv, Swapnila D ^a  

^a AISSMS COLLEGE OF PHARMACY   (India)

^b NONE   (India)

Author keywords

Buoyancy lag time; Effervescent FDDS; Full factorial design; HPMC; Salbutamol sulfate

Indexed keywords

BICARBONATE; CALCIUM PHOSPHATE DIBASIC; HYDROXYPROPYLMETHYLCELLULOSE; MAGNESIUM STEARATE; POVIDONE; SALBUTAMOL SULFATE; STEARIC ACID; TALC;

ARTICLE; COMPUTER PROGRAM; CURVE FITTING; DEPENDENT VARIABLE; DRUG ABSORPTION; DRUG FORMULATION; DRUG GRANULATION; DRUG RELEASE; DRUG SOLUBILITY; EFFERVESCENT TABLET; FACTORIAL DESIGN; GASTROINTESTINAL ABSORPTION; INDEPENDENT VARIABLE; MATHEMATICAL MODEL; MATRIX TABLET; VISCOSITY;

EID: 77953374452     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.49174     Document Type: Article

References (17)

1. Reynolds JE. Martindale-the extra Pharmacopoeia. Great Britain: Director of the Council of Royal Pharmaceutical Society of Great Britain; 2005. p. 362.
2. Swarbrick J, Boylon JC. Encyclopedia of Pharmaceutical Technology. New York: Marcel Dekker Inc; 200. p. 896.
3. Lipworth BJ, Clark RA, Dhillon D P, Charter MK, Palmer JB, McDevitt DG. Single dose and steady-state pharmacokinetics of 4 mg and 8 mg oral salbutamol controlled-release in patients with bronchial asthama. Eur J Clin Pharmacol 1989;37:49-52.
4. Goldstein DA, Tan YK, Soldin SJ. Pharmacokinetics and absolute bioavailability of albutamol in healthy adult volunteers. Eur J Clin Pharmacol 1987;32:631-4.
5. Pacifici GM, Giulianetti B, Quilici MC, Spisni R, Nervi M, Giuliani L, et al. (-)-Salbutamol sulphation in the human liver and duodenal mucosa: interindividual variability. Xenobiotica 1997;27:279-86.
6. Chavanpatil MD, Jain P, Chaudhari S, Shear R, Vavia PR. Novel sustained release, swellable and bioadhesive gastroretentive drug delivery system for ofloxacin. Int J Pharm 2006;316:86-92.
7. Singh BN, Kim KH. Floating drug delivery systems: An approach to oral controlled drug delivery via gastric retention. J Control Release 2000;63:35-259.
8. Hwang SJ, Park H, Park K. Gastric retentive drug-delivery systems. Crit Rev Ther Drug Carrier Syst 1998;15:243-84.
9. Bardonnet PL, Faivre V, Pugh WJ, Piffaretti JC, Falson F. Gastroretentive dosage forms: Overview and special case of Helicobactor pylori. J Control Rel 2006;111:1-18.
10. Rouge N, Buri P, Doelkar E. Drug absorption sites in the gastrointestinal tract and dosage for site-specific delivery. Int J Pharm 1996;136:117-39.
11. Umamaheshwari RB, Jain S, Bhadra D, Jain NK. Floating microspheres bearing acetohyxamic acid for the treatment of Helicobactor pylori. J Pharm Pharmacol 2003;55:607-13.
12. Jain SK, Awasthi AM, Jain NK, Agrawal G P. Calcium silicate based microsheres of rapiglinide for gastroretentive floating drug delivery: Preparation and in vitro characterization. J Control Rel 2005;107:300-9.
13. th ed. Available from: http://www.touchbriefings. com/cdps/cditem.cfm?NID-17andCID-5. [cited in 2003].
14. Singh B, Ahuja N. Response surface optimization of drug delivery system. In: Jain NK, editor. Progress in Controlled and Novel Drug Delivery System. New Delhi: CBS Publishers and Distributors; 2004. p. 470-509.
15. Singh B, Ahuja N. Development of controlled-release buccoadhesive hydrophilic matrices of diltiazem hydrochloride: optimization of bioadhesive, dissolution, and diffusion parameters. Drug Dev Ind Pharm 2002;28:431-42.
16. Siepmam J, Peppas NA. Modelling of drug release from delivery systems based on hydroxypropyl methyl cellulose (HPMC). Adv Drug Del Rel 2001;48:139-57.
17. Ritger PL, Peppas NA. A simple equation for description of solute release II. Fickian and anomalous release from swellable devices. J Control Release 1987;5:7-42.